- Home
- KNSA vs BIRK Comparison
KNSA vs BIRK Comparison
Compare KNSA & BIRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNSA | BIRK |
|---|---|---|
| Founded | 2015 | 1774 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.6B |
| IPO Year | 2018 | 2023 |
Fundamental Metrics
Financial Performance| Metric | KNSA | BIRK |
|---|---|---|
| Price | $77.19 | $30.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $60.86 | ★ $61.43 |
| AVG Volume (30 Days) | 415.4K | ★ 2.2M |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $677,564,000.00 | N/A |
| Revenue This Year | $37.48 | $13.71 |
| Revenue Next Year | $17.87 | $14.30 |
| P/E Ratio | $293.81 | ★ $17.48 |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $35.33 | $29.93 |
| 52 Week High | $82.94 | $50.73 |
Technical Indicators
Market Signals| Indicator | KNSA | BIRK |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 33.34 |
| Support Level | $44.95 | N/A |
| Resistance Level | $81.97 | $37.29 |
| Average True Range (ATR) | 2.39 | 1.08 |
| MACD | -0.39 | -0.04 |
| Stochastic Oscillator | 56.80 | 12.04 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
About BIRK Birkenstock Holding plc
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.